CytomX Therapeutics annual depreciation and amortization
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
CytomX Therapeutics Depreciation & Amortization Growth & History (CTMX)
CytomX Therapeutics's depreciation and amortization was $1.3M for fiscal 2025.
View full CytomX Therapeutics company overviewCytomX Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.3M | −$400,000 | −22.91% |
| 2024 | 2024-12-31 | $1.7M | −$400,000 | −18.64% |
| 2023 | 2023-12-31 | $2.1M | −$300,000 | −12.26% |
| 2022 | 2022-12-31 | $2.4M | −$300,000 | −10.92% |
| 2021 | 2021-12-31 | $2.7M | $200,000 | +7.86% |
| 2020 | 2020-12-31 | $2.5M | −$100,000 | −3.78% |
| 2019 | 2019-12-31 | $2.6M | $762,000 | +40.45% |
| 2018 | 2018-12-31 | $1.9M | $239,000 | +14.53% |
| 2017 | 2017-12-31 | $1.6M | −$88,000 | −5.08% |
| 2016 | 2016-12-31 | $1.7M | $527,000 | +43.70% |
| 2015 | 2015-12-31 | $1.2M | $423,000 | +54.02% |
| 2014 | 2014-12-31 | $783,000 | $128,000 | +19.54% |
| 2013 | 2013-12-31 | $655,000 | — | — |
CytomX Therapeutics quarterly depreciation and amortization
Q1.15
Q2.15
Q3.15
Q1.16
Q2.16
Q3.16
Q1.17
Q2.17
Q3.17
Q1.18
Q2.18
Q3.18
Q1.19
Q2.19
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $47,000 | −$300,000 | −86.46% |
| Q1 2026 | 2026-03-31 | $251,000 | — | — |
| Q4 2025 | 2025-12-31 | $510,000 | — | — |
| Q3 2025 | 2025-09-30 | $134,000 | — | — |
| Q2 2025 | 2025-06-30 | $347,000 | — | — |
| Q2 2019 | 2019-06-30 | $630,000 | $204,000 | +47.89% |
| Q1 2019 | 2019-03-31 | $617,000 | $241,000 | +64.10% |
| Q3 2018 | 2018-09-30 | $474,000 | −$3,000 | −0.63% |
| Q2 2018 | 2018-06-30 | $426,000 | $57,000 | +15.45% |
| Q1 2018 | 2018-03-31 | $376,000 | −$19,000 | −4.81% |
| Q3 2017 | 2017-09-30 | $477,000 | $34,000 | +7.67% |
| Q2 2017 | 2017-06-30 | $369,000 | −$76,000 | −17.08% |
| Q1 2017 | 2017-03-31 | $395,000 | $40,000 | +11.27% |
| Q3 2016 | 2016-09-30 | $443,000 | $136,000 | +44.30% |
| Q2 2016 | 2016-06-30 | $445,000 | $143,000 | +47.35% |
| Q1 2016 | 2016-03-31 | $355,000 | $87,000 | +32.46% |
| Q3 2015 | 2015-09-30 | $307,000 | — | — |
| Q2 2015 | 2015-06-30 | $302,000 | — | — |
| Q1 2015 | 2015-03-31 | $268,000 | — | — |
CytomX Therapeutics depreciation and amortization trends
Over the last five fiscal years, CytomX Therapeutics's depreciation and amortization decreased from $2.5M to $1.3M, a change of −$1.2M. The latest reported quarter, Q2 2026, shows $47,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review CytomX Therapeutics source filings ↗